The effect of nitric oxide donor sodium nitroprusside on glucose uptake in human primary skeletal muscle cells

Henstridge, Darren C., Drew, Brian G., Formosa, Melissa F., Natoli, Alaina K., Cameron-Smith, David, Duffy, Stephen J. and Kingwell, Bronwyn A. 2009, The effect of nitric oxide donor sodium nitroprusside on glucose uptake in human primary skeletal muscle cells, Nitric oxide, vol. 21, no. 2, pp. 126-131, doi: 10.1016/j.niox.2009.06.002.

Attached Files
Name Description MIMEType Size Downloads

Title The effect of nitric oxide donor sodium nitroprusside on glucose uptake in human primary skeletal muscle cells
Author(s) Henstridge, Darren C.
Drew, Brian G.
Formosa, Melissa F.
Natoli, Alaina K.
Cameron-Smith, David
Duffy, Stephen J.
Kingwell, Bronwyn A.
Journal name Nitric oxide
Volume number 21
Issue number 2
Start page 126
End page 131
Publisher Academica Press
Place of publication Boston, Mass.
Publication date 2009-09-15
ISSN 1089-8603
Keyword(s) nitric oxide
type 2 diabetes
human primary skeletal muscle cells
glucose uptake
Summary Nitric oxide (NO) has been implicated as an important signaling molecule in the insulin-independent, contraction-mediated glucose uptake pathway and may represent a novel strategy for blood glucose control in patients with type 2 diabetes (T2DM). The current study sought to determine whether the NO donor, sodium nitroprusside (SNP) increases glucose uptake in primary human skeletal muscle cells (HSkMC) derived from both healthy individuals and patients with T2DM. Vastus lateralis muscle cell cultures were derived from seven males with T2DM (aged 54 ± 2 years, BMI 31.7 ± 1.2 kg/m2, fasting plasma glucose 9.52 ± 0.80 mmol/L) and eight healthy individuals (aged 46 ± 2 years, BMI 27.1 ± 1.5 kg/m2, fasting plasma glucose 4.69 ± 0.12 mmol/L). Cultures were treated with both therapeutic (0.2 and 2 μM) and supratherapeutic (3, 10 and 30 mM) concentrations of SNP. An additional NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) was also examined at a concentration of 50 μM. Glucose uptake was significantly increased following both 30 and 60 min incubations with the supratherapeutic SNP treatments (P = 0.03) but not the therapeutic SNP doses (P = 0.60) or SNAP (P = 0.54). There was no difference in the response between the healthy and T2DM cell lines with any treatment or dose. The current study demonstrates that glucose uptake is elevated by supratherapeutic, but not therapeutic doses of SNP in human primary skeletal muscle cells derived from both healthy volunteers and patients with T2D. These data confirm that nitric oxide donors have potential therapeutic utility to increase glucose uptake in humans, but that SNP only achieves this in supratherapeutic doses. Further study to delineate mechanisms and the therapeutic window is warranted.
Language eng
DOI 10.1016/j.niox.2009.06.002
Field of Research 110306 Endocrinology
Socio Economic Objective 920104 Diabetes
HERDC Research category C1 Refereed article in a scholarly journal
HERDC collection year 2009
Copyright notice ©2009, Elsevier Inc
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Exercise and Nutrition Sciences
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 16 times in TR Web of Science
Scopus Citation Count Cited 16 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 757 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Wed, 30 Sep 2009, 12:29:45 EST by Sally Morrigan

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact